Syndax Pharmaceuticals, Inc. (SNDX) Stock Price & How to Invest
Last updated November 2026
Short answer
Syndax Pharmaceuticals is a commercial-stage oncology company based in New York with two FDA-approved medicines: Revuforj (revumenib), the first menin inhibitor ever approved, and Niktimvo (axatilimab-csfr), a CSF-1R blocking antibody for chronic graft-versus-host disease. The structural thing a screener gets wrong here is that only one of those two drugs reaches the revenue line as product sales. Incyte is the principal on every Niktimvo sale and books all of it, so Syndax records only its 50% share of net commercial profit as collaboration revenue, which is why the third quarter's $83.3M of reported revenue sat underneath roughly $128M of combined branded sales the two medicines actually generated. A separate $350M Royalty Pharma financing takes 13.8% off US Niktimvo net sales, and that cost lands in interest expense rather than in revenue or cost of goods. As of November 20, 2026 the shares closed at ~$8.95, down ~58% year to date and ~47.5% over one year, near a 52-week low of ~$8.41, after the Phase 2 MAXPIRe trial in idiopathic pulmonary fibrosis failed on October 12 and the frontline cGVHD readout with ruxolitinib slipped to the first quarter of 2027.
SNDX stock price
As of 2026-11-20, Syndax Pharmaceuticals, Inc. (SNDX) last closed at $8.72, down 50.0% over the past year. Over the past 52 weeks it has traded between $8.56 and $25.15.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Syndax Pharmaceuticals, Inc.'s investor relations page. Walnut is informational, not investment advice.
SNDX key stats
At $8.72 on November 20, 2026, Syndax Pharmaceuticals, Inc. (SNDX) has a market cap of $785M.
- Market cap
- $785M
- Beta
- 0.45
Market cap, P/E and yield are measured at the $8.72 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Syndax Pharmaceuticals, Inc. (SNDX)?
The last two weeks for Syndax Pharmaceuticals, Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- SNDX closed at $8.72 on November 20, 2026, down 7.7% over the past five trading days (from $9.45).
Syndax Pharmaceuticals, Inc. filed no current, quarterly or annual report with the SEC in the last two weeks.
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
Syndax Pharmaceuticals, Inc. (SNDX) latest quarter
Syndax Pharmaceuticals reported revenue of $83.3 million for Q3 2026, up 82% from a year earlier (Syndax Pharmaceuticals, Nov 2, 2026).
Source: Syndax Pharmaceuticals Q3 2026 results, Nov 2, 2026. Full earnings breakdown
What does Syndax Pharmaceuticals, Inc. (SNDX) do?
Syndax Pharmaceuticals (Nasdaq: SNDX) sells two approved medicines and funds a pipeline behind them. Revuforj (revumenib) is an oral menin inhibitor, approved by the FDA on November 15, 2024 for relapsed or refractory acute leukemia carrying a KMT2A translocation in patients one year and older, then expanded on October 24, 2025 into relapsed or refractory AML with a susceptible NPM1 mutation. Syndax owns it outright in the US, licensed originally from Vitae Pharmaceuticals, now an AbbVie subsidiary, and books its sales as product revenue. Niktimvo (axatilimab-csfr) is a first-in-class antibody against the CSF-1 receptor, approved in August 2024 for chronic graft-versus-host disease after at least two prior lines of systemic therapy in patients weighing 40kg or more. It was in-licensed from UCB Biopharma in 2016 and then partnered with Incyte in September 2021 under a worldwide co-development and co-commercialization agreement. Incyte runs the commercial engine and records the sales; Syndax takes half the net commercial profit. In the third quarter of 2026 Revuforj generated about $61M of net product revenue on roughly 1,700 prescriptions, while Niktimvo generated about $67M of net sales, of which $22.6M reached Syndax as collaboration revenue. The company employed about 298 people at last count.
The financial picture is a launch curve running into a fixed cost base. Total revenue went from $23.7M in 2024 to $172.4M in 2025 to ~$290M for the twelve months to September 30, 2026, and the third quarter alone was $83.3M, up 82% year over year and a little ahead of the ~$81.9M consensus. Operating expenses barely moved over that stretch: total opex was $211.8M for the first half of 2026 against $210.9M a year earlier, and management has reaffirmed full-year R&D plus SG&A to approximately $400M excluding roughly $50M of non-cash stock compensation, down from $438.5M in 2025. Operating loss narrowed accordingly, from $153.1M in the first half of 2025 to $74.2M in the first half of 2026, though the net loss held near $49M a quarter in both the second and third quarters. What the market is paying for sits mostly outside those numbers. Revuforj and Niktimvo are both approved only in later-line settings, and the registrational trials that would move revumenib into newly diagnosed AML (EVOLVE-2 and REVEAL-ND) and axatilimab into frontline cGVHD are still reading out, and the Phase 2 frontline cGVHD combination with ruxolitinib has been pushed from late 2026 to the first quarter of 2027. One expansion has already closed: on October 12, 2026 Syndax reported that the 145-patient MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis did not meet its primary endpoint (annualized decline in forced vital capacity), and the company does not plan further development in IPF. The stock fell about 16% after hours on the news. The second- and third-quarter losses of $0.55 a share were both wider than consensus (~$0.44 and ~$0.48). At ~$8.95 on November 20, 2026, down ~58% for the year, ~55% over three months and ~33% over the past month, the equity is capitalised around $806M, with about $551M of cash and investments at September 30, 2026 against roughly $589M of debt, most of it the Royalty Pharma liability and the convertible notes.
What's driving Syndax Pharmaceuticals, Inc. (SNDX)?
1. Revuforj moving from KMT2A into the far larger NPM1 population
The original November 2024 approval covered KMT2A-rearranged acute leukemia, a genuinely rare subset. The October 24, 2025 label expansion added relapsed or refractory AML with a susceptible NPM1 mutation, which is roughly a third of adult AML and several times the size of the first indication. The revenue trace since then shows the effect: $44.2M in the fourth quarter of 2025, $48.9M in the first quarter of 2026, $54.7M in the second and about $61M in the third (up 90% year over year and 11% sequentially), with prescriptions of about 1,700 in the latest quarter, up 13% sequentially, and roughly 300 new patients. Management has described a run of consecutive quarters of double-digit net revenue and prescription growth, and attributes part of it to longer average treatment duration as more patients stay on drug in the post-transplant setting.
2. Niktimvo, where Syndax sees half the profit and none of the sales line
Niktimvo net sales were about $67M in the third quarter of 2026, up 47% year over year and 12% sequentially, after $60.3M in the second quarter and $151.6M across all of 2025. Syndax's reported figure was $22.6M, helped by a one-time adjustment that lifted the profit share to about 34% of net sales; management guides that ratio to the low-to-mid 30s going forward, because the agreement splits net commercial profit (net product revenue minus cost of sales and commercial expenses) rather than revenue. Two consequences follow. Syndax's line is inherently lumpier than the drug's own trajectory, since a quarter of heavier commercial investment by Incyte compresses the profit share even while sales grow. And a screener computing gross margin or price-to-sales on Syndax will be working from a number that has already had manufacturing and selling costs deducted from half the franchise. The October 2026 IPF failure removes the largest non-transplant market axatilimab was being tested in, so Niktimvo's growth case now runs through cGVHD alone: the Phase 2 combination with ruxolitinib in newly diagnosed patients (topline now expected in the first quarter of 2027, delayed from late 2026) and a Phase 3 combination with steroids (readout expected in early 2028).
3. Frontline AML, which is what the valuation is actually about
Every approved use of Revuforj today is in relapsed or refractory disease, where patients are few and treatment durations are short. The company has two registrational Phase 3 trials aimed at newly diagnosed patients: EVOLVE-2, testing revumenib with venetoclax and azacitidine in NPM1-mutated and KMT2A-rearranged AML patients unfit for intensive chemotherapy, run with the HOVON network, and REVEAL-ND, testing revumenib with intensive chemotherapy in newly diagnosed NPM1-mutated AML. Supporting investigator-led work has been encouraging, including a Journal of Clinical Oncology publication in June 2026 from the Phase 1/2 SAVE trial reporting an 88% overall response rate and 71% composite complete remission in 42 heavily pretreated patients. Whether that translates into a registrational frontline result is the difference between a couple of hundred million in annual sales and something much larger. EVOLVE-2 uses complete remission rate as a dual primary endpoint, measured against historical controls in the low-to-mid 30s percent. Syndax has 19 abstracts accepted at ASH 2026, seven of them oral presentations, and is holding an investor event on December 14, 2026 alongside the meeting, where longer follow-up from the BEAT AML and SAVE frontline combinations is planned. After the IPF setback, more of the company's value hangs on these trials.
4. Expenses flat while revenue triples
Syndax spent $438.5M on R&D and SG&A in 2025 building out two simultaneous launches. The 2026 guide, reaffirmed in November, is approximately $400M excluding around $50M of estimated non-cash stock compensation, so the absolute spend is coming down while revenue rises. Second-quarter SG&A fell to $41.5M from $43.8M as the 2025 launch costs did not repeat, and R&D rose only to $68.0M from $62.2M despite the frontline trial expansion. Cash used in operating activities dropped from $183.0M in the first half of 2025 to $80.6M in the first half of 2026, and cash and investments ended September at about $551M, down from $575.1M in June. Management states it expects existing cash plus product, collaboration and interest income to carry the company to profitability, though no date is attached to that.
What are the risks to Syndax Pharmaceuticals, Inc. (SNDX)?
Revuforj no longer has the menin inhibitor class to itself. Kura Oncology and Kyowa Kirin won FDA approval for ziftomenib (Komzifti) in November 2025 in relapsed or refractory NPM1-mutated AML, the same population Syndax entered three weeks earlier, and began selling on November 21, 2025. Komzifti is dosed once daily. Both labels carry boxed warnings, including differentiation syndrome and QTc prolongation, so the competition is likely to be fought on dosing convenience, payer access and combination data rather than on a clean safety separation. Kura's partner paid $330M upfront with up to $1.1B in milestones, which funds a serious commercial effort against a Syndax field force that is already carrying two products. Johnson & Johnson and Sumitomo also have menin inhibitors in development. The balance sheet is the second issue. Total stockholders' equity was $15.1M at June 30, 2026 against $688.6M of liabilities, and the accumulated deficit stands at about $1.6B; trailing net losses of ~$209M have eroded that thin cushion further since. The financing is unusual in shape: a $350M upfront from Royalty Pharma in November 2024 that sells 13.8% of US Niktimvo net sales with aggregate payments capped at $822.5M, accounted for as debt, plus $250M of 2.25% convertible senior notes due June 2031 issued in June 2026 at a conversion price near $24.76. Royalty interest expense alone was $12.1M in the second quarter and $24.0M for the half, and it grows as Niktimvo grows. If Niktimvo performs, Syndax pays back up to 2.35 times what it received. The converts add about 10.1M potential shares against 89.4M outstanding. Beyond that, revenue depends on two products in narrow later-line indications, both under UCB and AbbVie-related royalty obligations, with the frontline expansions still unproven. The first quarter of 2026 already showed how sensitive the line is to the January payer reset, falling to $64.9M from $68.7M in the fourth quarter of 2025 despite underlying demand growth. Pipeline risk has already shown up once. The MAXPIRe Phase 2 trial in idiopathic pulmonary fibrosis (145 patients, 26 weeks, axatilimab 0.3 mg/kg every two weeks against placebo) missed its primary endpoint on October 12, 2026, though safety was comparable to placebo. Syndax said the result does not affect trials in other indications, and BofA cut its target to $23 from $26 while keeping a Buy rating. The second readout that mattered, axatilimab plus ruxolitinib in frontline cGVHD, then slipped to the first quarter of 2027, and the company is also going through a chief financial officer transition. The third-quarter loss of $0.55 a share missed the ~$0.48 consensus, the second miss in a row, and the shares fell from ~$13.11 on October 16 to ~$8.95 on November 20, 2026, close to the 52-week low of ~$8.41. UBS cut its target to $31 from $33 on November 20 while keeping a Buy rating.
What is the Syndax Pharmaceuticals, Inc. (SNDX) forecast?
11 analysts publish price targets on SNDX, averaging $34.00 as of November 2026, or +289.9% against the $8.72 share price on November 20, 2026. The published targets run from $17.00 to $57.00, a wide spread, and the ratings split 12 buy, 0 hold, 0 sell. Over the last six months there have been 0 raises and 4 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full SNDX forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is SNDX a buy or a sell?
We give no verdict on Syndax Pharmaceuticals, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. Revuforj moving from KMT2A into the far larger NPM1 population. The original November 2024 approval covered KMT2A-rearranged acute leukemia, a genuinely rare subset. The most optimistic published target, $57.00, assumes this works close to its best case.
The case against. Revuforj no longer has the menin inhibitor class to itself. The most pessimistic target, $17.00, is roughly what SNDX is worth if this bites instead.
Read the full bull and bear case on SNDX, including what would have to change to break either one. Walnut is not an investment adviser.
Has Syndax Pharmaceuticals, Inc. (SNDX) split its stock?
No. Syndax Pharmaceuticals, Inc. (SNDX) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.
How is Syndax Pharmaceuticals, Inc. (SNDX) valued?
Market cap, P/E and dividend yield at today's price are in the SNDX key stats above. The business figures below come from Syndax Pharmaceuticals, Inc.'s reported results as of November 2026 and change when it next reports.
- Revenue (TTM): ~$289.7M for the twelve months to September 30, 2026, against $172.4M in fiscal 2025 and $23.7M in fiscal 2024. The quarterly path was $68.7M in 4Q25, $64.9M in 1Q26 (a sequential dip driven by the January payer and gross-to-net reset, not by demand), $72.8M in 2Q26 and $83.3M in 3Q26, the last of which was up ~82% year over year.
- Product mix (the line that misleads screeners): Of 3Q26's $83.3M, about $61M was Revuforj net product revenue and $22.6M was collaboration revenue representing Syndax's 50% share of Niktimvo net commercial profit, on about $67M of Niktimvo net sales. Combined branded sales of the two medicines were therefore ~$128M in 3Q26 and over $275M across full-year 2025 ($124.8M Revuforj plus $151.6M Niktimvo), well above the reported revenue line.
- Earnings and EPS: Net loss of $49.4M, or $0.55 per share, in 3Q26, level with 2Q26; trailing twelve-month net loss of ~$209.5M, or ~$2.37 per share. Full-year 2025 net loss was $285.4M and 2024 was $318.8M. There is no P/E, and there has never been an annual profit; consensus has the loss narrowing to ~$0.65 a share in 2027.
- Operating expenses and guidance: Full-year 2026 guidance, reaffirmed with third-quarter results, is approximately $400M of R&D plus SG&A excluding ~$50M of estimated non-cash stock compensation, down from $438.5M actual in 2025. First-half opex was $211.8M against $210.9M a year earlier, so spend is roughly flat while revenue keeps climbing. Trailing operating margin is about -62%.
- Cash flow and balance sheet: Cash, cash equivalents and investments of about $551M at September 30, 2026, down from $575.1M at June 30 and up from $394.1M at December 31, 2025 after the $250M convertible issue. Trailing operating cash burn was ~$177M and free cash flow ~-$113M. Total debt of ~$589M, mainly the Royalty Pharma royalty financing liability and the 2.25% convertible notes due 2031; stockholders' equity was just $15.1M at June 30, 2026.
- Market pricing: ~$8.95 a share on November 20, 2026 for a market capitalisation of ~$806M, against a 52-week range of $8.41 to $25.59; the stock is down ~58% year to date, ~55% over three months and ~47.5% over one year. That works out to ~2.8x trailing sales. No dividend and no P/E.
As of November 2026: Roughly 2.8 times trailing sales is a low multiple for a biotech growing revenue at ~82%, and the reasons are visible in the structure and the pipeline more than the growth rate. Half the franchise arrives as a profit share, the Royalty Pharma instrument skims 13.8% of US Niktimvo sales before anything reaches Syndax, both drugs are approved only in later-line settings, the October 2026 IPF failure removed one route to a much larger market, and the frontline cGVHD readout has moved into 2027. At ~$806M, the market value is only about $255M above the ~$551M of cash and investments, while ~$589M of debt sits ahead of shareholders. Eleven covering analysts carry a mean target near $34, a frontline-expansion number and not a run-rate one.
Who competes with Syndax Pharmaceuticals, Inc. (SNDX)?
Menin inhibitors and targeted AML therapy
The direct rival is ziftomenib (Komzifti) from Kura Oncology and Kyowa Kirin, approved in November 2025 for relapsed or refractory NPM1-mutated AML and dosed once daily against Revuforj's twice-daily regimen. Johnson & Johnson has bleximenib in clinical development and Sumitomo Pharma has its own menin inhibitor in the clinic, so the class is likely to get more crowded. Beyond menin, Revuforj competes for the same treatment slot with AbbVie and Genentech's venetoclax (Venclexta), which it is also being combined with, Astellas's gilteritinib (Xospata) in FLT3-mutated disease, Servier's ivosidenib (Tibsovo) and Daiichi Sankyo's quizartinib (Vanflyta). Genotype determines much of the competitive overlap, since these agents target different mutations within the same disease.
Chronic GVHD and fibrotic disease
Niktimvo's position in cGVHD is third-line and after, so the incumbents ahead of it are Incyte's own ruxolitinib (Jakafi), Sanofi's belumosudil (Rezurock) and ibrutinib (Imbruvica) from AbbVie and Johnson & Johnson. Incyte is therefore both the partner booking Niktimvo's sales and the owner of the frontline standard the drug is being tested on top of, which is an unusual alignment. The Phase 2 combination with ruxolitinib in newly diagnosed patients now reads out in the first quarter of 2027, later than the fourth-quarter 2026 timing first planned. A parallel Phase 2 in idiopathic pulmonary fibrosis, which would have put axatilimab up against Boehringer Ingelheim's nintedanib (Ofev) and Roche's pirfenidone (Esbriet), missed its primary endpoint in October 2026 and will not advance.
Commercial-stage oncology mid-caps competing for capital
For an investor screening the sector, SNDX sits alongside other recently commercial oncology companies of similar size where the multiple is set by launch trajectory rather than earnings: Kura Oncology, Nuvalent, Day One Biopharmaceuticals and Rigel Pharmaceuticals among them. What separates Syndax within that group is that it already has two approved products and a meaningful revenue base, and that it has funded itself through royalty monetisation and convertible debt rather than repeated equity issuance. Share count grew only from 87.4M to 89.2M over the eighteen months to June 2026, which is unusual for a company of this profile.
What stocks are similar to Syndax Pharmaceuticals, Inc. (SNDX)?
Other names that sit close to SNDX: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Syndax Pharmaceuticals, Inc. (SNDX)
There are three common ways to get SNDX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so SNDX sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where SNDX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Syndax Pharmaceuticals, Inc. (SNDX)
As of November 2026, SNDX is a two-product commercial launch story priced at roughly 2.8 times trailing revenue, where the reported top line understates the drugs by design and the capital structure, not the share count, carries most of the financing. Third-quarter revenue of $83.3M rose 82% year over year and came in slightly above expectations, but the loss of $0.55 a share was wider than the ~$0.48 consensus. With the pulmonary fibrosis expansion abandoned, the valuation rests more heavily on moving revumenib from relapsed disease into frontline AML and axatilimab into frontline cGVHD.
More on Syndax Pharmaceuticals, Inc. (SNDX)
Whether SNDX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is SNDX a buy or a sell?, and where the stock could go from here in the SNDX stock forecast.
For income investors, whether SNDX pays a dividend and how the payout looks is covered in does SNDX pay a dividend? And to weigh SNDX against a peer, read the full side-by-side comparisons: SNDX vs JNJ and SNDX vs ABBV.
Wondering how SNDX fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Syndax Pharmaceuticals, Inc.
Ask Walnut's AI anything about SNDX and see how it fits what you own.
FAQ
What does Syndax Pharmaceuticals do?
+
Syndax is a commercial-stage biopharmaceutical company headquartered in New York that develops and sells cancer and immune-mediated disease therapies. It has two FDA-approved medicines. Revuforj (revumenib) is an oral menin inhibitor approved in November 2024 for relapsed or refractory acute leukemia with a KMT2A translocation and expanded in October 2025 into relapsed or refractory AML with a susceptible NPM1 mutation. Niktimvo (axatilimab-csfr) is an antibody blocking the CSF-1 receptor, approved in August 2024 for chronic graft-versus-host disease after at least two prior lines of systemic therapy. Behind those, Syndax is running Phase 3 trials to move revumenib into newly diagnosed AML and testing axatilimab in frontline cGVHD; a Phase 2 in idiopathic pulmonary fibrosis missed its primary endpoint in October 2026 and that program has been dropped. Two earlier-stage programmes, an allosteric EGFR inhibitor for lung cancer and a next-generation menin inhibitor for myelofibrosis, are targeted for INDs in 2027.
Why is SNDX revenue lower than its drug sales?
+
Because only one of the two drugs flows through as product revenue. Syndax partnered axatilimab with Incyte in September 2021, and under accounting rules for collaboration arrangements Incyte is the principal in product sales. Incyte therefore records all Niktimvo revenue, and Syndax records only its 50% share of net commercial profit, defined as net product revenue minus cost of sales and commercial expenses. In the third quarter of 2026 that meant about $67M of Niktimvo net sales produced $22.6M of collaboration revenue at Syndax. Revuforj, which Syndax owns outright in the US, is recorded gross at about $61M in the same quarter. Anyone computing price-to-sales or gross margin from the reported top line is mixing a gross number with a net-of-costs profit share, which makes both ratios non-comparable to a conventional specialty pharmaceutical company.
Is SNDX profitable?
+
No. Syndax reported a net loss of $49.4M, or $0.55 per share, in the third quarter of 2026, the same as in the second quarter, and about $209.5M over the trailing twelve months. Full-year 2025 was a $285.4M loss and 2024 was $318.8M. The trend has improved: the operating loss narrowed from $153.1M in the first half of 2025 to $74.2M in the first half of 2026, because revenue more than doubled while total operating expenses stayed essentially flat at around $212M. Operating cash burn fell from $183.0M to $80.6M over the same comparison. Management has said it expects existing cash together with product revenue, collaboration revenue and interest income to carry the company to profitability, but no target date has been given, analysts still expect a loss of ~$0.65 a share in 2027, and the accumulated deficit stands at roughly $1.6B.
Who are SNDX's competitors?
+
In menin inhibition, the direct competitor is ziftomenib (Komzifti) from Kura Oncology and Kyowa Kirin, approved in November 2025 for the same relapsed or refractory NPM1-mutated AML population Revuforj entered three weeks earlier. Komzifti is once daily; Revuforj is twice daily. Both labels carry boxed warnings including differentiation syndrome and QTc prolongation. Johnson & Johnson's bleximenib and a Sumitomo Pharma menin inhibitor are in development. Within AML more broadly, Revuforj sits alongside AbbVie and Genentech's venetoclax, Astellas's gilteritinib, Servier's ivosidenib and Daiichi Sankyo's quizartinib, which target different genotypes. In chronic GVHD, Niktimvo is used after Incyte's ruxolitinib, Sanofi's belumosudil and ibrutinib, so its own partner also owns the frontline standard it is being combined with in ongoing trials.
Why did SNDX stock drop?
+
The shares have traded between $8.41 and $25.59 over the past year and closed at ~$8.95 on November 20, 2026, down ~58% for the year and ~33% over the past month. The first sharp move came on October 12, 2026, when the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis missed its primary endpoint and the stock fell about 16% after hours; Syndax said it will not pursue IPF further. Third-quarter results on November 2 added to the pressure: revenue of $83.3M was up 82% and slightly above expectations, but the $0.55 loss per share missed the ~$0.48 consensus for a second straight quarter, the frontline cGVHD readout with ruxolitinib was delayed to the first quarter of 2027, and a CFO transition was under way. Earlier pressures were already in place. Kura Oncology and Kyowa Kirin's ziftomenib was approved in November 2025 in the same NPM1-mutated indication Revuforj had just entered, ending a brief monopoly. First-quarter 2026 revenue then fell sequentially to $64.9M from $68.7M as the January payer and gross-to-net reset hit. In June 2026 the company issued $250M of convertible notes with a conversion price near $24.76, adding about 10.1M potential shares against 89.4M outstanding.
Does SNDX pay a dividend?
+
No. Syndax has never paid a dividend and does not currently generate net income, so there is no distributable profit. The company is spending roughly $400M a year on research and selling costs against ~$290M of trailing revenue and is funding the gap from a cash and investments balance of about $551M at September 30, 2026, built partly from a $350M royalty monetisation and $250M of convertible notes. Both of those instruments carry claims that rank ahead of shareholders: the notes pay 2.25% semi-annual cash interest, and Royalty Pharma takes 13.8% of US Niktimvo net sales up to an $822.5M cap. Companies at this stage of a launch generally reinvest any surplus into trials rather than returning it, and Syndax's stated priority is reaching profitability rather than distributions.
How much cash does Syndax have, and will it need to raise more?
+
Syndax held about $551M in cash, cash equivalents and investments at September 30, 2026, down from $575.1M at June 30 and up from $394.1M at the end of 2025 after issuing $250M of 2.25% convertible senior notes due 2031 in June. Operating cash use in the first half of 2026 was $80.6M, and trailing free cash flow was about -$113M, falling as revenue grows against a flat cost base. On that arithmetic the balance covers several years, and management states it expects cash plus revenue and interest income to reach profitability without further financing. The caveats are real: the trials that matter most, the frontline AML Phase 3 programmes, are the most expensive part of the plan, total debt is about $589M, and stockholders' equity was only $15.1M at June 30, 2026, so the cushion is in the cash balance and not in the equity.
What are the next catalysts for SNDX in 2026?
+
The American Society of Hematology meeting in December carries most of what is left in 2026. Syndax has 19 Revuforj and Niktimvo abstracts accepted at ASH 2026, including seven oral presentations, and hosts an investor event on December 14, 2026, with longer follow-up and an expanded cohort from the BEAT AML and SAVE frontline revumenib combinations planned for the fourth quarter. One of the two axatilimab Phase 2 readouts has already arrived: on October 12, 2026 the MAXPIRe trial in idiopathic pulmonary fibrosis missed its primary endpoint, and Syndax dropped the indication. The other, combining axatilimab with ruxolitinib in newly diagnosed chronic GVHD, has been delayed to the first quarter of 2027, with a Phase 3 combination with steroids due to read out in early 2028. Syndax also expects safety and efficacy data in relapsed or refractory NUP98-rearranged acute leukemia, and two new trials start around the same window: RAVEN in the second half of 2026 and the MenTain post-transplant maintenance study around year end. The registrational EVOLVE-2 and REVEAL-ND Phase 3 trials are still enrolling.
How did Syndax do in its latest quarter?
+
In the third quarter of 2026, reported November 2, Syndax posted total revenue of $83.3M, up 82% year over year and a little above the ~$81.9M consensus. Revuforj net product revenue was about $61M, up 90% from a year earlier on roughly 1,700 prescriptions, and Niktimvo collaboration revenue was $22.6M on about $67M of net sales. The net loss was $49.4M, or $0.55 per share, wider than the ~$0.48 consensus. Cash and investments were about $551M at quarter end, the 2026 expense guide of ~$400M was reaffirmed, and the frontline cGVHD Phase 2 readout moved to the first quarter of 2027.
What happened with the axatilimab IPF trial?
+
On October 12, 2026 Syndax reported topline results from MAXPIRe, a 26-week, placebo-controlled Phase 2 trial of axatilimab in 145 patients with idiopathic pulmonary fibrosis. It did not meet its primary endpoint, the annualized rate of decline in forced vital capacity. Safety was comparable to placebo with no new signals. Syndax does not plan further development in IPF and said the result does not affect its cGVHD trials. The shares fell about 16% after hours.
How has SNDX stock performed in 2026?
+
As of the November 20, 2026 close at ~$8.95, SNDX was down ~58% year to date, ~55% over three months, ~33% over the past month and ~47.5% over one year, trading just above its 52-week low of $8.41 (the high was $25.59). The mean target among 11 analysts is ~$34. Walnut is not an investment adviser and does not tell anyone whether to buy or sell SNDX.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Syndax Pharmaceuticals, Inc.'s investor relations page or your broker before making investment decisions.